Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
4
×
national blog main
alnylam pharmaceuticals
boston
boston blog main
boston top stories
drugs
fda
rna interference
aminolevulinic acid
givosiran
onpattro
patisiran
san francisco blog main
san francisco top stories
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akcea therapeutics
akin akinc
andrew fire
cannabidiol
craig mello
dravet syndrome
epidiolex
fen-phen
fenfluramine
gw pharmaceuticals
hereditary transthyretin amyloidosis
inotersen
john maraganore
lennox-gastaut syndrome
national top stories
new york blog main
new york top stories
nobel prize
paul matteis
pfizer
san diego blog main
What
drug
medicine
4
×
pharmaceuticals
4
×
alnylam
fda
rnai
ago
approved
data
interference
market
ok
rna
second
seek
speedy
weeks
afternoon
alnylam’s
approval
battle
cannabis
cleared
derivative
epilepsy
far
form
gets
gw
gw’s
history
indicated
landmark
making
marijuana
nasdaq
new
nod
onpattro
patisiran
Language
Current search:
xconomy.com
×
medicine
×
" life sciences "
×
pharmaceuticals
×
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug